What Aventis SA does

Aventis SA merged with Sanofi-Synthélabo in 2004 to form what is now Sanofi, a French-domiciled, publicly traded global biopharmaceutical company headquartered in Paris. The current entity operates as an R&D-driven, AI-powered biopharmaceutical business with a pipeline of 77 compounds in clinical development across five therapeutic areas — Immunology, Neurology, Oncology, Rare Diseases, and Vaccines — and 21 Phase 3 trials.

Its product portfolio includes newly approved specialty medicines such as Cenrifki (tolebrutinib), approved in the EU as the first disability-targeting therapy for secondary progressive multiple sclerosis without relapses, and Wayrilz, approved in Japan for immune thrombocytopenia. Underlying the franchise is an AI-integrated R&D platform that spans drug discovery, development, and manufacturing, complemented by technology platforms organized around each therapeutic area and a specialized vaccines manufacturing capability. A separate consumer healthcare brand, Opella, was spun off as a standalone entity, providing OTC distribution through pharmacies and retail channels.

The company generates revenue primarily from the sale of proprietary prescription biopharmaceuticals and vaccines across its five therapeutic areas, with pricing negotiated through government health systems, insurers, and healthcare institutions rather than publicly disclosed. GTM motion is large-scale enterprise field sales to hospitals, clinics, and physicians, supplemented by direct engagement with national and regional government health authorities for vaccine procurement and a separate consumer health channel via Opella. Operating geographies span France, the United States, China, Japan, and Ireland, with an External Innovation network covering North America, Europe, and China.

Name

Aventis SA

Legal name

Sanofi

Website

https://aventis.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Aventis SA merged into Sanofi in 2004; the current entity is Sanofi, a publicly traded French biopharmaceutical company developing branded prescription drugs and vaccines across immunology, neurology, oncology, rare diseases, and vaccines for global healthcare providers, governments, and patients.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Biopharmaceutical products
• Prescription medicines
• Human vaccines
• Clinical development
• Therapeutic areas

Headquarters

HQ city

Strasbourg

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Biopharmaceutical Products: Revenue generated from the sale of proprietary medicines, vaccines, and biopharmaceutical products across multiple therapeutic areas including Immunology, Neurology, Oncology, Rare Diseases, and Vaccines.
2. Consumer Healthcare (Opella): Consumer healthcare products sold through Opella, Sanofi's consumer healthcare brand covering over-the-counter medicines and health products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Aventis S.A. is engaged in the discovery, development, manufacture, and marketing of branded prescription drugs and human vaccines. Through its successor entity Sanofi, the company operates an R&D-driven, AI-powered biopharmaceutical business spanning five therapeutic areas (Immunology, Neurology, Oncology, Rare Diseases, and Vaccines) with 77 compounds in clinical development and 21 Phase 3 trials. It also distributes over-the-counter consumer healthcare products via the Opella brand.

Product overview

Aventis SA (now part of Sanofi following the 2004 merger) is an R&D-driven, AI-powered biopharmaceutical company with 77 compounds in clinical development across 5 therapeutic areas (Immunology, Neurology, Oncology, Rare Diseases, and Vaccines). The portfolio includes marketed products like Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis and Wayrilz for immune thrombocytopenia, alongside a consumer healthcare brand (Opella). The company integrates AI throughout its R&D operations and maintains a robust clinical trial program with 21 Phase 3 trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Cenrifki (tolebrutinib) First-in-class prescription drug approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses.
• Wayrilz Prescription drug approved in Japan to treat immune thrombocytopenia (ITP).
• Consumer Healthcare (Opella) Consumer healthcare brand distributing over-the-counter medicines and health products through pharmacies and retail channels, serving as Sanofi's vehicle for the consumer health market.

Quantifiable outcome

• 21 clinical trials in phase 3
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• STATION FcoreStrategic or Co-development PartnerSanofi x STATION F partnership, placing Sanofi within one of the world's largest startup campuses to foster innovation, digital health collaborations, and co-development opportunities with emerging technology companies in France.
• OpellacoreOthersOpella is Sanofi's consumer healthcare brand, formed from the spin-off of Sanofi's consumer healthcare division. Opella operates as a separate entity focused on over-the-counter medicines and health products, serving as Sanofi's vehicle for the consumer health market.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Roche Holding AG: Global pharma leader with major presence in neurology (Ocrevus in MS — direct competitor to Sanofi's Cenrifki), oncology, and immunology. Roche is a directly comparable R&D-driven innovator with similar therapeutic-area breadth and global commercial scale.
• AbbVie Inc. Global biopharmaceutical leader with dominant immunology (Humira/Skyrizi/Rinvoq) and oncology franchises that compete directly with Sanofi's Dupixent and oncology pipeline. AbbVie is a closely comparable specialty-pharma peer with similar scale and pipeline strategy.
• Eli Lilly and Company: Major global pharmaceutical competitor with leading franchises in immunology (Taltz), neurology, oncology, and diabetes/endocrinology. Lilly is a directly comparable R&D-driven innovator with overlapping therapeutic areas and global scale.
• Pfizer Inc. One of the world's largest biopharmaceutical companies with parallel exposure to oncology, vaccines, rare diseases, and immunology. Pfizer competes directly with Sanofi across multiple therapeutic areas and operates a comparable global manufacturing and commercialization footprint.
• Novartis AG: Swiss-headquartered global pharmaceutical company with overlapping franchises in neurology (multiple sclerosis), immunology, oncology, and rare diseases. Novartis competes head-to-head with Sanofi in specialty care and operates a similarly diversified specialty-pharma model following its Sandoz spin-off.
• Merck & Co., Inc. Major R&D-driven biopharma company with strong oncology (Keytruda franchise), vaccines, and specialty portfolios. Merck is a directly comparable competitor in pipeline-driven specialty pharma and competes with Sanofi in overlapping indications.
• Bristol Myers Squibb Company: Specialty biopharma with material oncology, immunology, and rare disease franchises overlapping Sanofi's portfolio. BMS is a directly comparable competitor in pipeline-driven specialty therapeutics with similar regulatory and commercial dynamics.
• AstraZeneca plc: Global biopharma with strong oncology, rare disease, and immunology pipelines that overlap directly with Sanofi's portfolio. AstraZeneca's R&D-driven specialty-pharma model and global commercial footprint make it a closely comparable peer.
• GSK plc: UK-headquartered global pharma with material vaccines, specialty medicines, and immunology franchises. GSK is a directly comparable peer given its parallel vaccines business (where both companies hold significant share) and specialty/HIV franchises.

Broad incumbents

• Johnson & Johnson (Innovative Medicine): Diversified healthcare conglomerate with a large Innovative Medicine pharmaceutical division competing in immunology, oncology, and neuroscience. J&J is a broader incumbent peer given its wider consumer and medtech portfolio beyond pure biopharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sanofi

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aventis SA